Tags

Type your tag names separated by a space and hit enter

[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Rev Neurol 2012; 55(7):421-30RN

Abstract

Spasticity remains a prevalent symptom in multiple sclerosis, with a significant associated disability and quality of life impairment. A significant improvement in therapy aimed at reducing multiple sclerosis relapses and modifying its course has been achieved in recent years. Both general and specific traditional treatments have, however, major limitations. Thus, its use in real practice is lower than expected. Cannabinoids provide a new way for therapy. A delta-9-tetrahydrocannabinol plus cannabidiol (1:1) association, administered through an oromucosal route, has been approved in several countries including Spain; it causes a specific effect on CB(1) and CB(2) receptors, with traditional psychotropic cannabis actions being minimized. Randomized, placebo-controlled trials, as well as longer-term open-label extensions, have shown a clear-cut efficacy to reduce spasticity and their associated symptoms in those patients refractory to other therapies, with a good tolerability/safety profile. No tolerance, abuse or addictive issues have been found. New studies will be needed to find out potential new cannabinoid-related therapies.

Authors+Show Affiliations

Unidad de Esclerosis Múltiple, Servicio de Neurología, Hospital Clínico San Carlos, IdISSC, Madrid, España. orejacbn@gmail.com

Pub Type(s)

Journal Article
Review

Language

spa

PubMed ID

23011861

Citation

Oreja-Guevara, Celia. "[Treatment of Spasticity in Multiple Sclerosis: New Perspectives Regarding the Use of Cannabinoids]." Revista De Neurologia, vol. 55, no. 7, 2012, pp. 421-30.
Oreja-Guevara C. [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids]. Rev Neurol. 2012;55(7):421-30.
Oreja-Guevara, C. (2012). [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids]. Revista De Neurologia, 55(7), pp. 421-30.
Oreja-Guevara C. [Treatment of Spasticity in Multiple Sclerosis: New Perspectives Regarding the Use of Cannabinoids]. Rev Neurol. 2012 Oct 1;55(7):421-30. PubMed PMID: 23011861.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids]. A1 - Oreja-Guevara,Celia, PY - 2012/9/27/entrez PY - 2012/9/27/pubmed PY - 2013/4/6/medline SP - 421 EP - 30 JF - Revista de neurologia JO - Rev Neurol VL - 55 IS - 7 N2 - Spasticity remains a prevalent symptom in multiple sclerosis, with a significant associated disability and quality of life impairment. A significant improvement in therapy aimed at reducing multiple sclerosis relapses and modifying its course has been achieved in recent years. Both general and specific traditional treatments have, however, major limitations. Thus, its use in real practice is lower than expected. Cannabinoids provide a new way for therapy. A delta-9-tetrahydrocannabinol plus cannabidiol (1:1) association, administered through an oromucosal route, has been approved in several countries including Spain; it causes a specific effect on CB(1) and CB(2) receptors, with traditional psychotropic cannabis actions being minimized. Randomized, placebo-controlled trials, as well as longer-term open-label extensions, have shown a clear-cut efficacy to reduce spasticity and their associated symptoms in those patients refractory to other therapies, with a good tolerability/safety profile. No tolerance, abuse or addictive issues have been found. New studies will be needed to find out potential new cannabinoid-related therapies. SN - 1576-6578 UR - https://www.unboundmedicine.com/medline/citation/23011861/[Treatment_of_spasticity_in_multiple_sclerosis:_new_perspectives_regarding_the_use_of_cannabinoids]_ L2 - http://www.revneurol.com/LinkOut/formMedLine.asp?Refer=2012362&Revista=RevNeurol DB - PRIME DP - Unbound Medicine ER -